Mechanism behind common Parkinson's mutation discovered

February 5, 2018 by Will Doss, Northwestern University
Lipid reduction using an FDA-approved glucosylceramide synthase inhibitor (GCSi) reduces pathological alpha-synuclein in cell bodies (top) and neurites (bottom) of Parkinson’s patient neurons. Yellow staining indicates pathological alpha-synuclein. Credit: Northwestern University

Northwestern Medicine investigators have discovered how a gene mutation results in buildup of a toxic compound known to cause Parkinson's disease symptoms, defining for the first time the mechanism underlying that aspect of the disease.

The study, published in Neuron, points to a potential novel therapeutic pathway using drugs originally intended to treat another condition, Gaucher's disease, according to senior author Joseph Mazzulli, Ph.D., assistant professor in The Ken & Ruth Davee Department of Neurology, Division of Movement Disorders.

In Parkinson's, a protein called alpha-synuclein is converted to insoluble, toxic clusters in the central nervous system—but the exact mechanism of conversion was unknown until now.

One of the strongest risk factors for developing these clusters is a mutation in the gene GBA1, which normally degrades a lipid called glucosylceramide. Patients with one mutation in the gene suffer an increased level of glucosylceramide and have been shown to have a five-fold increased risk for Parkinson's; patients with two mutant forms of the gene, one inherited from each parent, can develop Gaucher's disease, a .

Mazzulli and his colleagues used this genetic connection to elucidate the mechanism of GBA1-influenced Parkinson's disease. Using stem cell models of neurons, they used a pharmacological inhibitor to increase levels of glucosylceramide without a mutated GBA1 gene. Even without the mutation, this resulted in a dramatic build-up of toxic alpha-synuclein in neurons.

"This suggested to us that the critical factor in converting alpha-synuclein from its normal form to its pathogenic form was not necessarily the presence of the mutated GBA1 protein, but more importantly the decreased activity and accumulation of glucosylceramide," Mazzulli said.

With that realization in mind, the investigators took a closer look at the conversion process, finding the healthy form of alpha-synuclein actually existed in two different forms, a simple molecule and a more complex molecule. While it was assumed previously that only the simple molecule was converted into the toxic variety, Mazzulli and his colleagues unexpectedly found the complex molecule was directly converted by glucosylceramide into toxic alpha-synuclein.

"We were surprised to find that toxic aggregation occurred by direct conversion of the large alpha-synuclein complex," Mazzulli said. "We thought the complex would have to first disassemble before forming toxic aggregates, but that's not what our data indicated."

These discoveries suggest that future therapies targeting this pathway might utilize drugs originally intended for treating Gaucher's disease, Mazzulli said. While the pharmaceutical industry has been interested in the use of those lipid-reducing agents for some time, this study defines the molecular process behind those efforts and demonstrates how it might work.

"Some companies have been using synthase inhibitors to reduce the synthesis of the lipid, and we used a similar compound on patient-derived neurons in our study," Mazzulli said. "We were able to show it reduced toxic alpha-synuclein aggregation directly within neurons derived from Parkinson's patients."

In addition, the study gives future drug trials an important metric to measure success, Mazzulli said.

"Our ultimate goal is to reduce levels in patients, however measuring the levels of alpha synuclein from the central nervous system of a living patient is complicated," Mazzulli said. "It's far easier to measure the effects of therapeutics that alter glucosylceramide in patients, since the lipid can be directly measured from easily accessible fluids, such as blood or cerebral spinal fluid."

The next step towards a functional treatment will be to graduate from stem cell-derived neurons to animal models, according to Mazzulli.

"We're trying to determine if this occurs in a living animal and if we can reverse it using similar compounds to what's being tested in these clinical trials," Mazzulli said. "If we can intervene before any insoluble amyloid protein develops, maybe we can reverse it to its normal state."

Explore further: Tug of war between Parkinson's protein and growth factor

Related Stories

Tug of war between Parkinson's protein and growth factor

September 18, 2017
Alpha-synuclein, a sticky and sometimes toxic protein involved in Parkinson's disease (PD), blocks signals from an important brain growth factor, Emory researchers have discovered.

Drug discovery: Alzheimer's and Parkinson's spurred by same enzyme

July 3, 2017
Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

New findings point to potential therapy for Parkinson's Disease

December 19, 2017
A new study, published in Proceedings of the National Academy of Sciences (PNAS), sheds light on a mechanism underlying Parkinson's disease and suggests that Tacrolimus—an existing drug that targets the toxic protein interaction ...

Balance and movement improved in animal model of Parkinson's disease

June 12, 2017
Researchers at UCLA have developed a molecular compound that improves balance and coordination in mice with early stage Parkinson's disease. Further, the drug, called CLR01, reduced the amount of a toxic protein in the brain ...

Researchers find new path to promising Parkinson's treatment

September 19, 2017
Three researchers at The University of Alabama are part of work that is leading to a new direction for drug discovery in the quest to treat Parkinson's disease.

SUMO defeats protein aggregates that typify Parkinson's disease

July 11, 2011
A small protein called SUMO might prevent the protein aggregations that typify Parkinson's disease (PD), according to a new study in the July 11, 2011, issue of The Journal of Cell Biology.

Recommended for you

Study uncovers cause of pesticide exposure, Parkinson's link

May 23, 2018
A new University of Guelph study has discovered why exposure to pesticides increases some people's risk of developing Parkinson's disease.

Link between tuberculosis and Parkinson's disease discovered

May 22, 2018
The mechanism our immune cells use to clear bacterial infections like tuberculosis (TB) might also be implicated in Parkinson's disease, according to a new collaborative study led by scientists from the Francis Crick Institute ...

Link between IBD and Parkinson's might allow doctors to slow down condition

May 21, 2018
Doctors may be able to modify or slow down the progress of the neurological condition Parkinson's disease in the future by spotting signs of it in patients with inflammatory bowel disease (IBD), suggest a study published ...

Untangling brain neuron dysfunction in Parkinson's disease and dementia with Lewy bodies

May 10, 2018
A decay of brain function is a hallmark of Parkinson's disease and dementia with Lewy bodies, or DLB. Specifically, cognitive dysfunction defines DLB, and nearly eight of every 10 Parkinson's patients develop dementia.

Diverse Parkinson's-related disorders may stem from different strains of same protein

May 9, 2018
Different Parkinson's-related brain disorders, called synucleionpathies, are characterized by misfolded proteins embedded in cells. Researchers in the Perelman School of Medicine at the University of Pennsylvania found that ...

New study sheds light on the complex dynamics of Parkinson's disease

May 3, 2018
Parkinson's disease affects around 10 million people worldwide, yet exactly how the disease and treatments for its symptoms work remains a bit mysterious. Now, Stanford researchers have tested a seminal theory of Parkinson's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.